Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design,Advanced Drug Delivery Reviews

当前位置： X-MOL 学术 › Adv. Drug Deliver. Rev. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design
Advanced Drug Delivery Reviews ( IF 15.2 ) Pub Date : 2024-04-26 , DOI: 10.1016/j.addr.2024.115322
Jennifer Stevenson ₁ , Rachel Poker ₂ , Johanna Schoss ₃ , Michael Campbell ₄ , Claire Everitt ₅ , Brian Holly ₅ , Nicholas Stones ₆ , Ronald J Pettis ₇ , Manuel Sanchez-Felix ₈

Affiliation

Subcutaneous (SC) drug delivery can be a safe, effective alternative to the traditional intravenous route of administration, potentially offering notable advantages for both patients and healthcare providers. The SC Drug Development & Delivery Consortium convened in 2018 to raise awareness of industry challenges to advance the development of patient-centric SC drug delivery strategies. The SC Consortium identified better understanding of patient preferences and perspectives as necessary to optimize SC product design attributes and help guide design decisions during SC product development. This manuscript provides a comprehensive overview of patient-centric factors for consideration in the SC drug delivery design and development process with the aim of establishing a foundation of existing knowledge for patient experiences related to SC drug delivery. This overview is informed by the outcomes of a multi-step survey of Consortium members and key pharmaceutical stakeholders. Framed in the context of the patient’s treatment journey, the survey findings offer future perspectives to fill data gaps to advance patient-centric SC drug delivery.

中文翻译：

制药和生物技术行业对通过皮下给药设计优化患者体验和治疗依从性的看法

皮下（SC）给药可以成为传统静脉给药途径的安全、有效的替代方案，可能为患者和医疗保健提供者提供显着的优势。 SC 药物开发和输送联盟于 2018 年召开，旨在提高人们对行业挑战的认识，以推动以患者为中心的 SC 药物输送策略的开发。 SC 联盟认为，更好地了解患者偏好和观点是优化 SC 产品设计属性并帮助指导 SC 产品开发期间的设计决策所必需的。本手稿全面概述了 SC 药物输送设计和开发过程中需要考虑的以患者为中心的因素，旨在为 SC 药物输送相关患者体验的现有知识奠定基础。本概述基于对联盟成员和主要制药利益相关者进行的多步骤调查的结果。调查结果以患者的治疗历程为背景，为填补数据空白以推进以患者为中心的皮下给药提供了未来的前景。

更新日期：2024-04-26

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南